PL1623719T3 - Leczenie choroby Alzheimer´a i mózgowej angiopatii amyloidowej - Google Patents

Leczenie choroby Alzheimer´a i mózgowej angiopatii amyloidowej

Info

Publication number
PL1623719T3
PL1623719T3 PL04730882T PL04730882T PL1623719T3 PL 1623719 T3 PL1623719 T3 PL 1623719T3 PL 04730882 T PL04730882 T PL 04730882T PL 04730882 T PL04730882 T PL 04730882T PL 1623719 T3 PL1623719 T3 PL 1623719T3
Authority
PL
Poland
Prior art keywords
disease
alzheimer
treatment
amyloid angiopathy
cerebral amyloid
Prior art date
Application number
PL04730882T
Other languages
English (en)
Inventor
Barrio Manuel Sarasa
Original Assignee
Araclon Biotech Sl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Araclon Biotech Sl filed Critical Araclon Biotech Sl
Publication of PL1623719T3 publication Critical patent/PL1623719T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Virology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)
PL04730882T 2003-05-08 2004-05-03 Leczenie choroby Alzheimer´a i mózgowej angiopatii amyloidowej PL1623719T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
ES200301054A ES2246105B1 (es) 2003-05-08 2003-05-08 Uso de anticuerpos para el tratamiento de enfermedades amiloideas.
PCT/ES2004/000194 WO2004098631A1 (es) 2003-05-08 2004-05-03 Método de tratamiento de la enfermedad de alzheimer
EP04730882A EP1623719B1 (en) 2003-05-08 2004-05-03 Treatment of alzheimer's disease and cerebral amyloid angiopathy

Publications (1)

Publication Number Publication Date
PL1623719T3 true PL1623719T3 (pl) 2010-11-30

Family

ID=32982086

Family Applications (3)

Application Number Title Priority Date Filing Date
PL10012342T PL2356996T3 (pl) 2003-05-08 2004-05-03 Leczenie choroby Alzheimera
PL08170222T PL2075007T3 (pl) 2003-05-08 2004-05-03 Leczenie choroby Alzheimera
PL04730882T PL1623719T3 (pl) 2003-05-08 2004-05-03 Leczenie choroby Alzheimer´a i mózgowej angiopatii amyloidowej

Family Applications Before (2)

Application Number Title Priority Date Filing Date
PL10012342T PL2356996T3 (pl) 2003-05-08 2004-05-03 Leczenie choroby Alzheimera
PL08170222T PL2075007T3 (pl) 2003-05-08 2004-05-03 Leczenie choroby Alzheimera

Country Status (19)

Country Link
US (6) US20090162362A1 (pl)
EP (5) EP2356996B9 (pl)
JP (5) JP2006525288A (pl)
CN (2) CN1784240A (pl)
AT (1) ATE435024T1 (pl)
AU (2) AU2004237373A1 (pl)
BR (1) BRPI0410684A (pl)
CA (1) CA2524571C (pl)
CY (1) CY1109454T1 (pl)
DE (1) DE602004021797D1 (pl)
DK (3) DK2075007T3 (pl)
ES (6) ES2246178B1 (pl)
IL (8) IL171651A (pl)
MX (1) MXPA05010914A (pl)
PL (3) PL2356996T3 (pl)
PT (3) PT2075007E (pl)
RU (2) RU2385161C2 (pl)
SI (1) SI1623719T1 (pl)
WO (1) WO2004098631A1 (pl)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10303974A1 (de) 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
US7732162B2 (en) 2003-05-05 2010-06-08 Probiodrug Ag Inhibitors of glutaminyl cyclase for treating neurodegenerative diseases
ES2246178B1 (es) * 2003-05-08 2007-03-01 Universidad De Zaragoza. Uso de anticuerpos para el tratamiento de enfermedades amiloideas.
SG190665A1 (en) 2004-07-30 2013-06-28 Rinat Neuroscience Corp Antibodies directed against amyloid-beta peptide and methods using same
MY148086A (en) 2005-04-29 2013-02-28 Rinat Neuroscience Corp Antibodies directed against amyloid-beta peptide and methods using same
CN101506236B (zh) 2005-11-30 2012-12-12 雅培制药有限公司 抗淀粉样β蛋白的单克隆抗体及其用途
RU2442793C2 (ru) 2005-11-30 2012-02-20 Эбботт Лэборетриз АНТИТЕЛА ПРОТИВ ГЛОБУЛОМЕРА Аβ, ИХ АНТИГЕНСВЯЗЫВАЮЩИЕ ЧАСТИ, СООТВЕТСТВУЮЩИЕ ГИБРИДОМЫ, НУКЛЕИНОВЫЕ КИСЛОТЫ, ВЕКТОРЫ, КЛЕТКИ-ХОЗЯЕВА, СПОСОБЫ ПОЛУЧЕНИЯ УКАЗАННЫХ АНТИТЕЛ, КОМПОЗИЦИИ, СОДЕРЖАЩИЕ УКАЗАННЫЕ АНТИТЕЛА, ПРИМЕНЕНИЯ УКАЗАННЫХ АНТИТЕЛ И СПОСОБЫ ИСПОЛЬЗОВАНИЯ УКАЗАННЫХ АНТИТЕЛ
RU2551782C2 (ru) 2005-12-12 2015-05-27 Ац Иммуне Са Специфические в отношении амилоида бета (а бета) 1-42 моноклональные антитела, обладающие терапевтическими свойствами
TWI551607B (zh) * 2006-07-14 2016-10-01 Ａｃ免疫公司 人類化抗體
US8455626B2 (en) 2006-11-30 2013-06-04 Abbott Laboratories Aβ conformer selective anti-aβ globulomer monoclonal antibodies
EP2124952A2 (en) 2007-02-27 2009-12-02 Abbott GmbH & Co. KG Method for the treatment of amyloidoses
EP2481408A3 (en) 2007-03-01 2013-01-09 Probiodrug AG New use of glutaminyl cyclase inhibitors
WO2008128985A1 (en) 2007-04-18 2008-10-30 Probiodrug Ag Thiourea derivatives as glutaminyl cyclase inhibitors
US8048420B2 (en) 2007-06-12 2011-11-01 Ac Immune S.A. Monoclonal antibody
US8613923B2 (en) 2007-06-12 2013-12-24 Ac Immune S.A. Monoclonal antibody
CA2701790A1 (en) * 2007-10-05 2009-04-16 Ac Immune S.A. Use of humanized anti-beta-amyloid antibody in ocular diseases
RU2482876C2 (ru) * 2007-10-05 2013-05-27 Дженентек, Инк. Применение антитела против амилоида-бета при глазных заболеваниях
EP2149380A1 (en) * 2008-07-29 2010-02-03 Medivet Pharma, S.L. Veterinary immunotherapy compositions for the Aged Related Cognitive Dysfunction.
EP2258398A1 (en) 2009-05-26 2010-12-08 Araclón Biotech, S. L. Albumin-amyloid peptide conjugates and uses thereof
CA2772488C (en) 2009-09-11 2018-04-17 Probiodrug Ag Heterocyclic derivatives as inhibitors of glutaminyl cyclase
PT2510359E (pt) 2009-12-11 2015-12-02 Araclón Biotech S L Métodos e reagentes para a deteção melhorada de péptidos beta-amiloides
JP6026284B2 (ja) 2010-03-03 2016-11-16 プロビオドルグ エージー グルタミニルシクラーゼの阻害剤
NZ602312A (en) 2010-03-10 2014-02-28 Probiodrug Ag Heterocyclic inhibitors of glutaminyl cyclase (qc, ec 2.3.2.5)
US8987419B2 (en) 2010-04-15 2015-03-24 AbbVie Deutschland GmbH & Co. KG Amyloid-beta binding proteins
JP5945532B2 (ja) 2010-04-21 2016-07-05 プロビオドルグ エージー グルタミニルシクラーゼの阻害剤としてのベンゾイミダゾール誘導体
JP5934203B2 (ja) * 2010-07-14 2016-06-15 メルク・シャープ・エンド・ドーム・コーポレイション 抗ａｄｄｌモノクローナル抗体およびこの使用
CN103179981B (zh) * 2010-07-30 2017-02-08 Ac免疫有限公司 安全和功能性的人源化抗β‑淀粉样蛋白抗体
CN103298833B (zh) 2010-08-14 2015-12-16 Abbvie公司 β淀粉样蛋白结合蛋白
EP2686313B1 (en) 2011-03-16 2016-02-03 Probiodrug AG Benzimidazole derivatives as inhibitors of glutaminyl cyclase
US10195257B2 (en) 2013-07-28 2019-02-05 Qantu Therapeutics, Inc. Vaccine formulations comprising quillaja desacylsaponins and beta amyloid peptides or tau protein to induce a Th2 immune response
ES2571055B1 (es) * 2016-02-15 2016-12-28 Araclon Biotech, S.L. Conjugado amiloide y usos y procedimientos del mismo
US12227567B2 (en) 2017-07-25 2025-02-18 Truebinding, Inc. Treating cancer by blocking the interaction of TIM-3 and its ligand
ES2812698T3 (es) 2017-09-29 2021-03-18 Probiodrug Ag Inhibidores de glutaminil ciclasa
PL237739B1 (pl) 2018-06-06 2021-05-17 Univ Gdanski Genisteina do zastosowania do leczenia choroby Alzheimera
CN116063520A (zh) 2019-01-30 2023-05-05 真和制药有限公司 抗gal3抗体及其用途
CN116157151A (zh) 2020-05-26 2023-05-23 真和制药有限公司 通过阻断半乳凝素-3治疗炎性疾病的方法

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1339014C (en) * 1987-10-08 1997-03-25 Ronald E. Majocha Antibodies to a4 amyloid peptide
AU5525090A (en) * 1989-04-14 1990-11-16 Research Foundation For Mental Hygiene, Inc. Monoclonal antibody to amyloid peptide
CA2081482C (en) 1990-04-27 2000-11-21 Ellis L. Kline Method and composition for treatment of central nervous system disease states associated with abnormal amyloid beta protein molecular organization
US5750349A (en) * 1993-01-25 1998-05-12 Takeda Chemical Industries Ltd. Antibodies to β-amyloids or their derivatives and use thereof
US7427392B1 (en) * 1994-11-14 2008-09-23 Elan Pharmaceuticals, Inc. Methods for aiding in the diagnosis of alzheimer's disease by measuring amyloid-β peptide (x-≧41) and tau
US8173127B2 (en) * 1997-04-09 2012-05-08 Intellect Neurosciences, Inc. Specific antibodies to amyloid beta peptide, pharmaceutical compositions and methods of use thereof
US6743427B1 (en) * 1997-12-02 2004-06-01 Neuralab Limited Prevention and treatment of amyloidogenic disease
TWI239847B (en) * 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
US7964192B1 (en) * 1997-12-02 2011-06-21 Janssen Alzheimer Immunotherapy Prevention and treatment of amyloidgenic disease
US6274119B1 (en) * 1998-08-20 2001-08-14 The Regents Of The Univ. Of California Methods for labeling β-amyloid plaques and neurofibrillary tangles
UA81216C2 (en) * 1999-06-01 2007-12-25 Prevention and treatment of amyloid disease
EP1975179A1 (en) * 2001-12-26 2008-10-01 Araclon Biotech, S.L. Polyclonal antibodies, preparation method thereof and use of same
EP1371986A1 (en) * 2002-06-06 2003-12-17 ABETA GmbH Diagnosis of Alzheimer's disease based on the hAbeta42:hAbeta40 ratio
CA2487528A1 (en) * 2002-07-24 2004-02-12 Innogenetics N.V. Prevention, treatment and diagnosis of diseases associated with beta-amyloid formation and/or aggregation
ES2201929B1 (es) * 2002-09-12 2005-05-16 Araclon Biotech, S.L. Anticuerpos policlonales, metodo de preparacion y uso de los mismos.
BR0315157A (pt) * 2002-10-09 2005-08-09 Rinat Neuroscience Corp Métodos de tratar doença de alzheimer empregando-se anticorpos direcionados contra peptìdeo beta amilóide e composições deste
UA87453C2 (ru) * 2003-02-01 2009-07-27 Вайет Применения фрагмента ав для лечения болезни альцгеймера
ES2246178B1 (es) * 2003-05-08 2007-03-01 Universidad De Zaragoza. Uso de anticuerpos para el tratamiento de enfermedades amiloideas.

Also Published As

Publication number Publication date
IL207877A0 (en) 2011-07-31
IL207878A0 (en) 2011-07-31
RU2005134351A (ru) 2006-04-27
CA2524571A1 (en) 2004-11-18
DK2356996T3 (da) 2013-07-22
PT2075007E (pt) 2013-08-23
EP2082747A3 (en) 2010-01-13
US20170260234A1 (en) 2017-09-14
ES2246178A1 (es) 2006-02-01
US20090162362A1 (en) 2009-06-25
DE602004021797D1 (de) 2009-08-13
IL207876A (en) 2013-03-24
SI1623719T1 (sl) 2009-12-31
CA2524571C (en) 2017-01-10
ES2246178B1 (es) 2007-03-01
EP2082747A2 (en) 2009-07-29
EP1623719A1 (en) 2006-02-08
IL207877A (en) 2013-03-24
CN101264326A (zh) 2008-09-17
DK2356996T5 (da) 2013-08-26
CY1109454T1 (el) 2014-08-13
EP2356996B1 (en) 2013-06-26
US20200140488A1 (en) 2020-05-07
IL207880A0 (en) 2011-07-31
IL207881A (en) 2013-02-28
EP2305286A2 (en) 2011-04-06
EP2075007B9 (en) 2013-09-04
ES2246177A1 (es) 2006-02-01
ES2246177B1 (es) 2007-03-01
IL207881A0 (en) 2011-07-31
DK2075007T3 (da) 2013-07-29
WO2004098631A1 (es) 2004-11-18
ES2246105A1 (es) 2006-02-01
ES2329369T3 (es) 2009-11-25
PT2356996E (pt) 2013-08-23
EP2075007B1 (en) 2013-05-22
US20110262458A1 (en) 2011-10-27
US20210214394A1 (en) 2021-07-15
PT1623719E (pt) 2009-10-08
EP2075007A2 (en) 2009-07-01
IL207879A (en) 2013-02-28
ATE435024T1 (de) 2009-07-15
EP2305286A3 (en) 2011-11-09
PL2075007T3 (pl) 2013-09-30
IL171651A (en) 2011-11-30
RU2009148539A (ru) 2011-06-27
IL207876A0 (en) 2011-07-31
JP2006525288A (ja) 2006-11-09
JP2014129389A (ja) 2014-07-10
AU2011200170C1 (en) 2012-03-22
IL207875A (en) 2013-02-28
BRPI0410684A (pt) 2006-06-20
AU2011200170B2 (en) 2011-09-01
EP2356996B9 (en) 2013-08-28
IL207878A (en) 2013-02-28
AU2004237373A1 (en) 2004-11-18
RU2526155C2 (ru) 2014-08-20
JP2012006967A (ja) 2012-01-12
DK1623719T3 (da) 2009-11-09
IL207880A (en) 2013-02-28
AU2011200170A1 (en) 2011-02-03
PL2356996T3 (pl) 2013-09-30
MXPA05010914A (es) 2006-03-21
EP2356996A1 (en) 2011-08-17
US20140044725A1 (en) 2014-02-13
RU2385161C2 (ru) 2010-03-27
EP1623719B1 (en) 2009-07-01
IL207875A0 (en) 2011-07-31
ES2423281T3 (es) 2013-09-19
ES2246105B1 (es) 2007-03-01
JP2016065100A (ja) 2016-04-28
CN1784240A (zh) 2006-06-07
ES2423590T3 (es) 2013-09-23
JP2018119011A (ja) 2018-08-02
IL207879A0 (en) 2011-07-31
EP2075007A3 (en) 2009-11-11

Similar Documents

Publication Publication Date Title
PL1623719T3 (pl) Leczenie choroby Alzheimer´a i mózgowej angiopatii amyloidowej
EP1613347A4 (en) BETA AMYLOID PEPTIDE DETECTING HUMANIZED ANTIBODIES
ES2414872T8 (es) Terapia combinada para la prevención o tratamiento de la enfermedad de Alzheimer y kit correspondiente
WO2002074240A3 (en) Anti-amyloid antibody based diagnosis and treatment of a neurological disease or disorder
PL352717A1 (pl) Profilaktyka i leczenie chorób amyloidogennych
ATE369380T1 (de) Impfstoff zur verhütung und behanldung von alzheimer-demenz und von amyloid-bezogenen krankheiten
EP1578988A4 (en) TNF-ALPHA VARIANT-BASED PROTEIN FOR TREATMENT OF TNF-ALPHA ASSOCIATED DISORDERS
EA200602015A1 (ru) Гуманизированные антитела, распознающие бета-амилоидный пептид
EA200501560A1 (ru) Предотвращение и терапия амилоидогенной болезни
EA200501891A1 (ru) Гуманизированные антитела, распознающие бета-амилоидный пептид
DK2172208T3 (da) Små peptider til behandling af alzheimers sygdom og andre beta-amyloidprotein- fibrillogeneseforstyrrelser
EP1543109A4 (en) SUBSTANCES FOR THE PREVENTION AND TREATMENT OF AUTOIMMUNE DISEASES
EP1749532A4 (en) MEDICINAL PRODUCTS FOR HEALING OR TREATING WOUNDS
WO2007021886A3 (en) Truncated memapsin 2 for use for treating alzheimer's disease
WO2005012330A3 (en) AMYLOID β-PEPTIDE AND METHODS OF USE
WO2010024927A3 (en) Treatment of amyloidoses using myelin basic protein and fragments thereof
WO2005044301A3 (en) Use of specific histones for the treatment of parasitic diseases
EP1614428A4 (en) MEDICAMENT FOR PREVENTING OR TREATING ANGIOGENIC EYE DISEASES
WO2003087835A8 (en) Haptoglobin fragments diagnostic of alzheimers disease
HK1063639A (en) Vaccine for the prevention and treatment of alzheimer's and amyloid related diseases
WO2005067957A3 (en) Use of a dg147 protein product for preventing and treating metabolic disorders